Supporting Information To:

Synthesis of Conformationally Locked Versions of Puromycin Analogues

Hisao Saneyoshi,¹ Benoît Y. Michel,² Yongseok Choi,¹ Peter Strazewski,²* Victor E. Marquez¹*

¹Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA, ² Université de Lyon, F–69622, Lyon, France; Université Claude Bernard Lyon 1, Villeurbanne; UMR 5246, CNRS, Laboratoire de Synthèse de Biomolécules.

*To whom correspondence should be addressed. Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute at Frederick, National Institutes of Health, 376 Boyles Street, Frederick, MD 21702. Phone: 301-846-5954. Fax: 301-846-6033. E-mails: <u>marquezv@mail.nih.gov</u> and <u>strazewski@univ-lyon1.fr</u> (for the compounds described on pages 37-123)

Table of contents

Compounds	Pages
General synthetic methods	3
Procedures for the synthesis of compounds in Schemes 2 and 3	
¹ H-NMR, ¹³ C-NMR, and HRMS data for compounds 22-25	15–18
12	19–20
14	21–22
16	23–24
18	25–26
6	
15	29–30
17	31–32
19	33–34
7	35–36
N,N-di-n-dibutylformamidine dimethylacetal (distilled)	
20	39–44
23	45–53
5 & 5.TFA	54–64
22	
4	74–80
21	81–88
25	
9	
24	
8	115–123

General synthetic methods

All chemical reagents were commercially available. Melting points are uncorrected. Flash column chromatography was performed on silica gel 60 (230-240 mesh) and analytical TLC was developed on silica gel GF. Unless otherwise indicated, NMR spectra were determined in CDCl₃ (99.8%) with residual CHCl₃ as the reference peak (7.26) in ¹H-NMR and the central peak of the CDCl₃ signal (77.0 ppm) in the ¹³C-NMR spectra. The spectra were recorded at 400 MHz, 300 MHz, or 500 MHz as indicated. The coupling constants are reported in Hertz and the peak shifts are reported in the δ (ppm) scale; abbreviations s (singlet), d (doublet), dd (doublet-of-doublets), ddd (doublet-of-doublet-of doublets), t (triplet), q (quartet), and m (multiplet). Positive-ion fast atom bombardment mass spectra (FABMS) were obtained at an accelerating voltage of 6 kV and a resolution of 2000; glycerol was used as the sample matrix, and ionization was effected by a beam of xenon atoms. The electrospray MS were obtained in cationic and anionic mode. Infrared spectroscopy was performed neat and specific optical rotations were measured in the indicated solvents. All reaction glassware was oven-dried and cooled to room temperature in an argon or dry nitrogen atmosphere prior to use.

Procedures for the synthesis of compounds in Schemes 2 and 3

1S,3S,4R,5S)-1-[6-(Dimethylamino)purin-9-yl]-4-(hydroxymethyl)bicyclo[3.1.0]-hexan-3-ol (12). Compound 11⁹ (651 mg, 1.41 mmol) was dissolved in a mixture consisting of an aqueous solution of 40% dimethylamine and EtOH (30 mL, 2:1, v/v) and heated in a sealed tube to 90 °C for 4 h. After cooling to room temperature and concentrated in vacuo, the residue was dissolved in MeOH (15 mL) under argon atmosphere and treated with 10% Pd-C (500 mg). The argon was then replaced with H₂ and stirred at room temperature for 15 h. The mixture was filtered through a Celite® pad and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluted with CHCl₃-MeOH (90/10 \rightarrow 85/15, v/v) to give 12 (354 mg, 87%) as a white solid: mp 176- 178° C; $[\alpha]^{20}_{D} = -42.0^{\circ}$ (c, 0.50, MeOH); ¹H-NMR (CD₃OD, 400 MHz) δ 1.34 (1H, ddd, J = 9.6, 5.3, 2.3 Hz, H-6'a), 1.60 (1H, pseudo t, $J \approx 5.2$ Hz, H-5'), 1.78 (1H, ddd, J = 9.6, 4.8, 1.2 Hz, H-6'b), 2.15 (1H, pseudo t, $J \approx 3.6$ Hz, H-4'), 2.18 (1H, d, J = 13.5 Hz, H-2'a), 2.50 (1H, ddd, J = 13.5, 7.0, 2.4 Hz, H-2'b), 3.45 (6H, br s, N(CH₃)₂), 3.78 (1H, dd, J = 11.5, 4.3 Hz, CHHOH), 3.96 (1H, dd, J = 11.3, 2.9 Hz, CHHOH), 4.33 (1H, d, J = 6.8 Hz, H-3'), 8.02 (1H, s, H-8), 8.14 (1H, s, H-2); ¹³C-NMR (CD₃OD, 100 MHz) δ 18.1, 28.2, 39.0, 43.6, 44.7, 53.5, 66.1, 76.3, 121.1, 141.4, 151.7, 152.6, 156.1; FAB-MS m/z (relative intensity) 290 (MH⁺, 100%). Anal. Calcd for C₁₄H₁₉N₅O₂: C, 58.12; H, 6.62; N, 24.21. Found: C, 58.09; H, 6.71; N, 24.06.

(1S.3S,4R,5S)-1-[6-(Dimethylamino)purin-9-yl]-4-[2.2-dimethyl-1,1-diphenyl-1-silapropoxy)methyl]bicyclo[3.1.0]hexan-3-ol (14). Compound 12 (244 mg, 0.843 mmol) was dissolved in pyridine (10 mL) and treated with imidazole (126 mg, 1.85 mmol) and TBDPS-Cl (476 mL, 1.85 mmol) at 0°C. The mixture was allowed to reach room temperature and stirred for 2 h. The reaction was guenched with MeOH (1 mL). Volatiles were removed *in vacuo*, and the residue extracted with EtOAc and brine. The organic solution was dried (MgSO₄) and filtered. The solution was evaporated *in vacuo* and the residue was purified by column chromatography on a silica gel eluted with CHCl₃/MeOH (95/5, v/v) to give 14 (434 mg, 98%) as a white foam: $[\alpha]^{20}_{D} = -43.4^{\circ}$ (c, 0.45, CHCl₃); ¹H-NMR (CDCl₃ 400 MHz) δ 1.08 (9H, s, t-Bu), 1.31 (1H, ddd, J = 9.5, 5.5, 2.0 Hz, H-6'a), 1.72 (1H, pseudo t, J \approx 5.2 Hz, H-5'), 1.80 (1H, ddd, J = 9.2, 4.9, 0.8 Hz, H-6'b), 2.27-2.33 (2H, m, H-2'a, H-4'), 2.48 (1H, ddd, J = 13.8, 6.7, 2.0 Hz, H-2'b), 3.49 (6H, br, N(CH₃)₂), 3.92 (1H, dd, J = 10.2, 7.0, Hz, CHHOSi), 3.99 (1H, J = 10.2, 8.1 Hz, CHHOSi), 4.41 (1H, d, J = 6.6 Hz, H-3'), 7.36-7.42 (5H, m, Ph-H), 7.43-7.72 (6H, m, Ph-H, H-8), 8.22 (1H, s, H-2); ¹³C-NMR (CDCl₃, 100 MHz) δ 17.8, 19.3, 26.1, 26.9, 38.5, 41.2, 42.5, 52.8, 65.3, 74.0, 120.5, 127.7, 129.7, 135.5, 135.6, 138.6, 151.4, 152.2, 154.9; FAB-MS m/z (relative intensity) 528.3 $(MH^+, 100\%)$; HRMS (FAB) calc for $(C_{30}H_{38}N_5O_2Si^+)$ 528.2795 (MH⁺), found 528.2820.

(1S.3R.4R.5S)-1-[6-(Dimethylamino)purin-9-yl]-4-[2,2-dimethyl-1,1-diphenyl-1-silapropoxy)methyl]bicyclo[3.1.0]hexan-3-ol (16). Compound 14 (230 mg, 0.436 mmol) was dissolved in CH₂Cl₂ (4 mL) and treated with the Dess-Martin periodinane reagent (277 mg, 0.653 mmol) at 0°C under argon. The mixture was allowed to reach room temperature and stirred for 4.5 h. After diluting with Et₂O (20 mL) the entire reaction mixture was poured into cold aqueous NaHCO₃ (10 mL) containing Na₂S₂O₃ (700 mg) and washed with brine. The organic solution was dried (MgSO₄), filtered, and evaporated *in vacuo*. The residue was dissolved in THF (4) mL) and treated with 1M L-selectride[®] in THF (567 µL) at -78°C under argon. After stirring for 30 min, the reaction was guenched with acetone (1 mL) and diluted with CHCl₃ (30 mL). The solution was extracted with aqueous NH₄Cl and then with brine, dried (MgSO₄), filtered, and evaporated *in vacuo*. The residue was purified by column chromatography on silica gel eluted with CHCl₃/MeOH (90/10, v/v) to give **16** (211 mg, 92%) as a white foam: $[\alpha]^{20}_{D} = -21.2^{\circ}$ (c, 0.20, CHCl₃); ¹H-NMR (CDCl₃, 400 MHz) δ 1.04-1.08 (1H, m, H-6'a), 1.08 (9H, s, t-Bu), 1.66-1.73 (2H, m, H-6'b, H-5'), 2.06 (1H, m, H-4'), 2.26 (1H, dd, J = 14.3, 4.6 Hz, H-2'a), 2.34 (1H, dd, J = 14.4, 4.4 Hz, H-2'b), 3.54 (6H, br, N(CH₃)₂), 4.05 (1H, dd, J = 10.2, 7.4, Hz, CHHOSi), 4.23 (1H, br s, H-3'), 4.29 (1H, dd, J = 10.4, 7.4 Hz, CHHOSi), 7.35-7.44 (5 H, m, Ph-H), 7.70-7.75 (6H, m, Ph-H, H-8), 8.27 (1H, s, H-2); ¹³C-NMR (CDCl₃, 100 MHz) & 19.2, 24.9, 26.8, 27.5, 38.4, 43.0, 44.4, 51.5, 63.9, 77.8, 120.4, 127.7, 129.6, 133.6, 133.7, 135.5, 135.6, 138.3, 150.5, 151.8, 154.8; FAB-MS m/z (relative intensity) 528.2 (MH⁺, 100%); Anal. Calcd for C₃₀H₃₇N₅O₂Si; C, 68.28; H, 7.07; N, 13.27. Found: C, 68.11, H, 7.26, N, 12.97.

(9-{(15,35,45,55)-3-Azido-4-[(2,2-dimethyl-1,1-diphenyl-1-silapropoxy)methyl]-bicyclo[3.1.0]hexyl}purin-6-yl)dimethylamine (18). Compound 16 (200 mg, 0.379 mmol) was co-evaporated 3 times with pyridine and dissolved in anhydrous pyridine (4 mL). After cooling to 0°C, the solution was treated with MsCl (59 µL, 0.759 mmol), allowed to reach room temperature, and stirred for 4 h. The reaction was guenched with H₂O (1 mL) and evaporated *in vacuo*. The residue was diluted with CHCl₃ (30 mL) and extracted with brine and aqueous NaHCO₃. The extract was dried (MgSO₄), filtered, and evaporated *in vacuo*. The residue was dissolved in DMF (15 mL) and treated with NaN₃ (493 mg, 7.58 mmol). The reaction mixture was stirred at 120 °C for 2 h. After cooling to room temperature it was diluted with Et₂O (100 mL) and the resulting organic solution and washed with H₂O and brine. The extract was dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by chromatography on silica gel eluted with hexane/EtOAc (70/30, v/v) to give 18 (148 mg, 71%) as a white foam: $[\alpha]^{20}_{D} = -34.2^{\circ}$ (c, 1.45, CHCl₃); IR (neat) 2099 cm⁻¹; ¹H-NMR (CDCl₃, 400 MHz) δ 1.09 (9H, s, t-Bu), 1.32 (1H, ddd, J = 9.3, 6.1, 2.2 Hz, H-6'a), 1.51 (1H, pseudo t, J \approx 5.4 Hz, H-5'), 1.66 (1H, dd, J = 9.5, 4.8 Hz, H-6'b), 2.19 (1H, d, J = 14.0 Hz, H-2'a), 2.39 (1H, dd, J = 9.2, 6.2 Hz, H-4'), 2.57 (1H, ddd, J = 13.9, 7.9, 1.9 Hz, H-2'b), 3.49 (6H, br, N(CH₃)₂), 3.96 (1H, dd, J = 10.4, 6.3 Hz, CHHOSi), 4.10 (1H, pseudo t, $J \approx 9.9$, Hz, CHHOSi), 4.25 (1H, d, J = 7.8 Hz, H-3'), 7.38-7.44 (6H, m, Ph-H), 7.62 (1H, s, H-8), 7.70-7.73 (4H, m, Ph-H), 8.17 (1H, s, H-2); ¹³C-NMR (CDCl₃, 100 MHz) δ 16.0, 19.3,

25.8, 26.9, 37.0, 38.5, 42.4, 50.2, 62.4, 64.6, 120.5, 127.8, 129.8, 133.4, 135.5, 135.6, 138.4, 151.4, 152.3, 154.8; FAB-MS m/z (relative intensity) 553.4 (MH⁺, 47.8%); HRMS (FAB) calc for (C₃₀H₃₇N₈OSi⁺) 553.2860 (MH⁺), found: 553.2878.

{(1*S*,2*S*,3*S*,5*S*)-3-Azido-5-[6-(dimethylamino)purin-9-yl]bicyclo[3.1.0]hex-2-yl] methan-1-ol (6). Compound 18 (126 mg, 0.228 mmol) was dissolved in THF (2 mL) and treated with 1M TBAF-THF (251 μL). After stirring at room temperature for 30 min, the solution was evaporated *in vacuo*. The residue was purified by column chromatography on silica gel eluted with hexane/EtOAc (1/1, v/v) to give 6 (64 mg, 89%) as white crystals: mp 109°C-111°C; $[\alpha]^{20}{}_{D}$ = +15.9° (c, 0.50,CHCl₃); IR (neat) 2102, 1595 cm⁻¹; ¹H-NMR (CDCl₃, 400 MHz) δ 1.32 (1H, ddd, *J* = 8.2, 5.8, 2.3 Hz, H-6'a), 1.51 (1H, pseudo t, *J* ≈ 5.3 Hz, H-1'), 1.66 (1H, dd, *J* = 9.5, 4.8 Hz, H-6'b), 2.19 (1H, d, *J* = 14.0 Hz, H-4a'), 2.30 (1H, d, *J* = 2.7 Hz, H-2'), 2.67 (1H, ddd, *J* = 14.0, 8.0, 1.9 Hz, H-4'b), 3.49 (6H, v br s, N(CH₃)₂), 3.96 (1H, br d, *CH*HOH), 4.10 (1H, d, *J* = 11.8 Hz, CHHOH), 4.25 (1H, d, *J* = 7.7 Hz, H-3'), 6.99 (1H, br s, 5'-OH), 7.80 (1H, s, H-8), 8.30 (1H, s, H-2); ¹³C-NMR (CDCl₃, 100 MHz) δ 16.2, 27.3, 38.6, 40.0, 43.1, 49.5, 64.5, 65.7, 120.1, 139.0, 150.1, 151.7, 154.9; FAB-MS m/z (relative intensity) 315.2 (MH⁺, 100%). HRMS (FAB) calc for (C₁₄H₁₉N₈O⁺) 315.1682 (MH⁺), found 315.1697.

(15.35,4R,55)-1-(6-Aminopurin-9-yl)-4-[(2,2-dimethyl-1,1-diphenyl-1-silapro-propoxy)methyl]bicyclo[3.1.0]hexan-3-ol (15). The known compound 13⁹ (415 mg, 1.59 mmol) was co-evaporated 3 times with pyridine and dissolved in anhydrous pyridine (5 mL). The solution was treated with TBDPS-Cl (613 µL, 2.39 mmol) at 0 °C and further stirred at room temperature for 1 h and treated again with TBDPS-Cl (204 µL, 0.794 mmol). After 10 min, the reaction was guenched with MeOH (1 mL) and evaporated in vacuo. The residue was diluted with CHCl₃ and washed with brine and aqueous NaHCO₃. The organic extract was dried (MgSO₄) and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluted with CHCl₃/MeOH (95/5, v/v) to give 15 (631 mg, 79%) as white crystals: mp 190°C-192°C; $[\alpha]^{20}_{D} = -41.9^{\circ}$ (c, 0.35, CHCl₃); ¹H-NMR (CDCl₃, 400 MHz) δ 1.07 (9H, s, *t*-Bu), 1.33 (1H, ddd, J = 9.5, 5.5, 1.9 Hz, H-6'a), 1.72 (1H, pseudo t, $J \approx 5.2$ Hz H-5'), 1.80-1.83 (1H, m, H-6'b), 2.27-2.33 (2H, m, H-2'a, H-4'), 2.49 (1H, ddd, J = 13.7, 6.7, 1.8 Hz, H-2'b), 3.90-4.04 (2H, m, CH₂OSi), 4.42 (1H, d, J = 6.6 Hz, H-3'), 6.03 (2H, br s, NH₂), 7.35-7.71 (11H, m, Ph-H, H-8), 8.20 (1H, s, H-2); ¹³C-NMR (CDCl₃, 100 MHz) δ 17.6, 19.3, 26.2, 26.9, 41.2, 42.7, 52.8, 65.2, 73.7, 119.7, 127.7, 129.8, 133.4, 135.5, 135.6, 135.7, 140.9, 150.8, 152.5, 155.1; FAB-MS m/z (relative intensity) 500.2 (MH⁺, 100%). Anal. Calcd for C₂₈H₃₃N₅O₂Si: C, 67.30; H, 6.66; N, 14.02. Found: C, 67.11; H, 6.61; N, 14.06.

(1*S*,3*R*,4*R*,5*S*)-1-(6-Aminopurin-9-yl)-4-[(2,2-dimethyl-1,1-diphenyl-1-silapro-popoxy)methyl]-bicyclo[3.1.0]hexan-3-ol (17). Compound 15 (250 mg, 0.500 mmol) was dissolved in CH₂Cl₂ (2 mL) and treated with the Dess-Martin periodinane reagent (318 mg, 0.745 mmol) at 0°C under argon. The reaction was allowed to reach room temperature and stirred for 3.5 h. After diluting with Et₂O (30 mL) the entire reaction mixture was poured into cold aqueous NaHCO₃ (10 mL) containing Na₂S₂O₃ (700 mg) and washed with brine. The organic solution was dried (MgSO₄), filtered, and evaporated in vacuo. The residue was dissolved in THF (5 mL) and treated with 1M L-selectride[®] in THF (750 µL) at -78°C under argon. After stirring for 60 min, the reaction was quenched with acetone (1 mL) and diluted with CHCl₃ (30 mL). The solution was extracted with aqueous NH_4Cl and then with brine, dried (MgSO₄), filtered, and evaporated *in vacuo*. The residue was purified by column chromatography on silica gel eluted with CHCl₃/MeOH (90/10, v/v) to give 17 (202 mg, 81%) as a yellowish foam: $[\alpha]^{20}_{D} = -10.1^{\circ}$ (c, 0.79, CHCl₃): ¹H-NMR (CDCl₃, 400 MHz) δ 1.07 (10H, s, H-6'a, t-Bu), 1.60 (1H, br dd, J = 9.2, 5.8 Hz, H-5'), 1.72 (1H, ddd, J = 9.4, 4.5, 1.8 Hz, H-6'b), 2.13-2.19 (1H, m, H-4'), 2.26 (1H, dd, J = 13.9, 3.1 Hz, H-2'a), 2.38 (1H, dd, J = 13.9, 5.2 Hz, H-2'b), 4.03 (1H, dd, J = 10.4, 7.3 Hz, CHHOSi), 4.21 (1H, dd, J = 9.3, 4.8 Hz, H-3'), 4.29 (1H, dd, J = 10.4, 7.2 Hz, CHHOSi), 6.32 (2H, br s, NH₂), 7.35-7.71 (11H, m, Ph-H, H-8), 8.25 (1H, s, H-2): ¹³C-NMR (CDCl₃, 100 MHz) δ 19.2, 23.0, 26.8, 27.0, 42.5, 43.5, 49.9, 63.9, 76.6, 119.7, 127.6, 129.7, 133.4, 135.5, 135.6, 140.6, 150.1, 152.3, 155.5; FAB-MS m/z (relative intensity) 500.4 (MH⁺, 100%); HRMS (FAB) calc for (C₂₈H₃₄N₅O₂Si⁺) 500.2482 (MH⁺), found 500.2485.

9-{(1S,3S,4S,5S)-3-Azido-4-[(2,2-dimethyl-1,1-diphenyl-1-silapropopoxy)methyl]-bicyclo-[3.1.0]hexyl}purin-6-ylamine (19). Compound 17 (170 mg, 0.340 mmol) was co-evaporated 3 times with pyridine and dissolved in anhydrous pyridine (4 mL). After cooling to 0°C, the solution was treated with MsCl (53 µL, 0.682 mmol) allowed to reach room temperature, and stirred for 1 h. The reaction was quenched with H₂O (1 mL) and evaporated *in vacuo*. The residue was diluted with EtOAc, washed with brine and H₂O, dried (MgSO₄), and evaporated *in vacuo*. The residue was then dissolved in DMF (10 mL) and reacted with NaN₃ (442 mg, 6.80 mmol) at 120 °C for 2 h. After reaching room temperature the reaction mixture was diluted with EtOAc and washed with H₂O and brine. The organic extract was dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography on silica gel eluted with hexane/EtOAc ($1/1 \rightarrow 1/2$, v/v) to give **19** (125 mg, 70%) as white crystals: mp 174°C-175°C; $[\alpha]^{20}_{D} = -49.2^{\circ}$ (c, 0.10, CHCl₃); IR (neat) 2103 cm⁻¹; ¹H-NMR (CDCl₃, 400 MHz) δ 1.10 (9H, s), 1.35 (1H, ddd, J = 9.4, 6.1, 1.9 Hz, H-6'a), 1.54 (1H, pseudo t, $J \approx 5.5$ Hz, H-5'), 1.70 (1H, dd, J = 9.6, 4.8 Hz, H-6'b), 2.20 (1H, d, J = 13.9 Hz, H-2'a), 2.40 (1H, dd, J = 8.7, 6.2 Hz, H-4'), 2.56 (1H, ddd, J = 13.9, 7.8, 1.8 Hz, H-2'b), 3.97 (1H, dd, J = 10.4, 6.2 Hz, CHHOSi), 4.08 (1H, dd, J = 10.3, 9.2 Hz, CHHOSi), 4.25 (1H, d, *J* = 7.7 Hz, H-3'), 6.01 (2H, br, NH₂), 7.38-7.73 (11H, m, Ph-H, H-8), 8.17 (1H, s, H-2); ¹³C- NMR (CDCl₃, 100 MHz) δ 16.1, 19.3, 25.9, 26.9, 37.3, 42.5, 50.1, 62.4, 64.7, 119.9, 127.8, 129.8, 133.3, 135.5, 135.6, 140.7, 150.8, 152.8, 155.4; FAB-MS m/z (relative intensity) 525.2 (100%). Anal. Calcd for C₂₈H₃₂N₈OSi•0.7H₂O: C, 62.59; H, 6.27; N, 20.85. Found: C, 62.62; H, 6.26; N, 20.81.

[(15,35,45,55)-5-(6-Aminopurin-9-yl)-3-azidobicyclo[3.1.0]hex-2-yl]methan-1-ol (7). A mixture of compound 19 (100 mg, 0.19 mmol) and NH₄F (35 mg, 0.945 mmol) was dissolved in MeOH (4 mL). After stirring at 60 °C for 24 h, the solution was evaporated *in vacuo*. The residue was purified by column chromatography on silica gel eluted with EtOAc/MeOH (90:10, v/v) to give 7 (50 mg, 93%) as white crystals. An analytical sample was recrystalized from EtOAc/MeOH: mp 217-218 °C (decomp.); $[\alpha]^{20}_{D} = -13.6^{\circ}$ (c, 0.10, CHCl₃); IR (neat) 2093 cm⁻¹; ¹H-NMR (CD₃OD, 400 MHz) δ 1.41 (1H, ddd, *J* = 9.6, 6.0, 2.2 Hz, H-6'a), 1.50 (1H, pseudo t, *J* \approx 5.5 Hz, H-1'), 1.87 (1H, ddd, *J* = 9.6, 4.8, 0.8 Hz, H-6'b), 2.28 (1H, t, *J* = 4.2 Hz, H-2'), 2.34 (1H, d, *J* = 13.8 Hz, H-4'a), 2.61 (1H, ddd, *J* = 13.8, 7.8, 2.2 Hz, H-4'b), 3.84 (1H, dd, *J* = 11.5, 4.4 Hz, CHHOH), 3.98 (1H, dd, *J* = 11.5, 4.2 Hz, CH*H*OH), 4.29 (1H, d, *J* = 7.7 Hz, H-3'), 8.16 (1H, s, H-8), 8.19 (1H, s, H-2); ¹³C-NMR (CD₃OD, 100 MHz) δ 17.2, 28.0, 40.1, 44.5, 51.0, 65.5, 65.9, 120.3, 143.4, 151.2, 153.5, 157.4; FAB-MS m/z (relative intensity) 287.2 (MH⁺, 100%); HRMS (FAB) calc for (C₁₂H₁₅N₈O⁺) 287.1369 (MH⁺), found 287.1380.

N,*N*-di-*n*-butylformamide dimethylacetal. Di-*n*-butyl formamide (50 mL) and fresh dimethyl sulfate (26 mL) were mixed under argon and heated to reflux (100° C) during 4 hours, then cooled to ambient temperature and stirred overnight. The mixture was worked up with ice-cold absolute MeOH (150 mL) into which sodium (8 g) had been dissolved before. After the temperature returned

to ambient, the solvent was evaporated under reduced pressure, diethyl ether was added under vigorous stirring and the precipitate was filtered off and rinsed with more ether. The filtrate was evaporated under reduced pressure and the oily residue was distilled *in vacuo* (bp 110-120 °C under oil pump vacuum: early fractions contain *N*,*N*-di-*n*-butylformamide dimethyl acetal, late fractions contain di-*n*-butyl formamide) to give a clear colorless or pale yellow oil that can be safely stored under an inert atmosphere in the cold; ¹H-NMR (CDCl₃, 300 MHz) δ 0.89 (6H, t, *J* = 7.2 Hz, N(CH₂CH₂CH₃)₂), 1.30 (4H, q, *J* = 7.2 Hz, N(CH₂CH₂CH₃)₂), 1.40 (4H, q, *J* = 7.5 Hz, N(CH₂CH₂CH₃)₂), 2.59 (4H, t, *J* = 7.2 Hz, N(CH₂CH₂CH₃)₂), 3.30 (6H, s, (OCH₃)₂), 4.51 (1H, s, NCH(OCH₃)₂); ¹³C-NMR (CDCl₃, 75 MHz) δ 13.9, 20.4, 30.9, 47.0, 53.6, 112.6.

(1*R*,2*S*,4*S*,5*S*)-4-{6-[1-aza-2-(dibutylamino)vinyl]purin-9-yl}-2-azidobicyclo[3.1.0]-hexyl)methan-1-ol (20). *N*,*N*-di-*n*butylformamide dimethylacetal (95 mg, 0.472 mmol) was added dropwise to a stirred solution of the azide derivative 3^8 (54 mg, 0.189 mmol) in MeOH (1.2 mL) at room temperature. During 1 h, the reaction mixture was stirred and heated for a few seconds with the heat gun every 15 min. The volatiles were removed *in vacuo* and the residue was purified by silica gel column chromatography (cyclohexanes/EtOAc, $1/1 \rightarrow 1/2 \rightarrow 1/3 \rightarrow 1/4 \rightarrow 1/5$, v/v) to give the protected amidine, which was co-evaporated from toluene to give **20** (80 mg, 99%) as a white solid: mp 113-117 °C; ¹H-NMR (CDCl₃, 300 MHz) δ 0.76–0.84 (1H, m, H-6'a), 0.84–0.92 (1H, m, H-6'b), 0.90 (6H, t, *J* = 6.3 Hz, N(CH₂CH₂CH₂CH₃)₂), 1.25–1.41 (4H, m, N(CH₂CH₂CH₂CH₃)₂), 1.54–1.70 (4H, m, N(CH₂CH₂CH₂CH₃)₂), 1.65–1.70 (1H, m, H-5'), 1.86–1.96 (1H, m, H-3'a), 2.10 (1H, dd, *J* = 14.7, 8.4 Hz, H-3'b), 3.35 (2H, t, *J* = 7.2 Hz, N(CH₂CH₂CH₂CH₃)₂), 3.42 (1H, d, J = 11.7 Hz, CHHOH), 3.66 (2 H, t, J = 5.6 Hz, N(CH₂CH₂CH₂CH₂CH₃)₂), 4.34 (1H, d, J = 11.7 Hz, CHHOH), 4.82 (1H, t, J = 8.9 Hz, H-2'), 4.96 (1H, d, J = 6.9 Hz, H-4'), 8.24 (s, 1H, H-8), 8.44 (s, 1H, H-2), 8.91 (s, 1 H, N=CHNBu₂); ¹³C-NMR (CDCl₃, 75 MHz) δ 10.7, 13.5, 13.8, 19.6, 20.1, 26.2, 29.1, 30.8, 36.2, 37.0, 45.1, 51.8, 56.4, 60.3, 63.3, 126.3, 141.1, 150.4, 152.0, 158.0, 160.1; HRMS (ESI⁺) calcd for (C₂₁H₃₂N₉O⁺) 426.2730 (MH⁺), found 426.2727.

((15,25,35,55)-5-{6-[1-Aza-2-(dibutylamino)vinyl]purin-9-yl}-3-azidobicyclo[3.1.0]-hex-2-yl)methan-1-ol (21). To a stirred solution of the azidopurine 7 (54 mg, 0.189 mmol) in MeOH (1.2 mL) was added dropwise *N*,*N*-di-*n*-butylformamide dimethylacetal (95 mg, 0.472 mmol) and the reaction mixture was stirred at room temperature for 1h and every 15 min, the solution was heated for a few seconds with the heat gun. The volatiles were removed *in vacuo* and the residue was purified by silica gel column chromatography (cyhexane/EtOAc $1/1 \rightarrow 1/2 \rightarrow 1/3 \rightarrow 1/4 \rightarrow 1/5$, v/v) to give the compound **22** (79 mg, 98 %) as a off-white oil: ¹H-NMR(CDCl₃, 300 MHz) δ 0.88–0.94 (6 H, m, N(CH₂CH₂CH₂CH₂CH₃)₂) 1.26–1.39 (5H, m, H-6'a, N(CH₂CH₂CH₂CH₃)₂), 1.49 (1H, t, *J* = 5.3 Hz, H-6'b), 1.55–1.68 (4H, m, N(CH₂CH₂CH₂CH₃)₂), 1.78 (1H, dd, *J* = 9.5, 4.7 Hz, H-1'), 2.22 (1H, d, *J* = 13.5 Hz, H-4'a), 2.31 (1H, br. s, H-2'), 2.70 (1H, dd, *J* = 12.6, 8.1 Hz, H-4'b), 3.37 (2H, t, *J* = 7.2 Hz, N(CH₂CH₂CH₂CH₃)₂), 3.68 (2H t, *J* = 7.5 Hz, N(CH₂CH₂CH₂CH₃)₂), 3.83 (1H, br. s, CHHOH), 4.09 (1H, d, *J* = 12.0 Hz, CHHOH), 4.33 (1H, d, *J* = 7.5 Hz, H-3'), 6.68 (1H, br. s, OH), 7.91 (1H, s, H-8), 8.46 (1H, s, H-2), 8.96 (1H, s, N=CHNBu₂); ¹³C-NMR (CDCl₃, 75 MHz) δ 13.6, 13.8, 16.2, 19.6, 20.1, 27.2,

29.1, 30.8, 40.1, 43.1, 45.2, 49.4, 51.9, 64.5, 65.7, 126.0, 142.3, 151.2, 152.0, 158.3, 160.3; HRMS (ESI⁺) calcd for (C₂₁H₃₂N₉O⁺) 426.2730 (MH⁺), found 426.2731.

¹H-NMR, ¹³C-NMR, and HRMS data for compounds 22-25

(2*S*)-*N*-{(1*R*,2*S*,4*S*,5*S*)-4-[6-(Dimethylamino)purin-9-yl)-1-(hydroxymethyl)bicyclo-[3.1.0]hex-2-yl}-2-[(fluoren-9-ylmethoxy)carbonylamino]-3-(4-methoxyphenyl)-propanamide (22).

¹H-NMR (CDCl₃, 300 MHz) δ 0.51–0.60 (2H, m, H-6'a,b), 1.56–1.66 (1H, m, H-5'), 1.62 (1H, dd, J = 8.1, 3.6 Hz, H-3'a), 1.99–2.08 (1H, m, H-3'b), 2.90–3.07 (2H, m, *p*-MeOPhCH₂), 3.18 (1H, d, J = 12.2 Hz, CHHOH), 3.50 (1H, br s, NMe₂), 3.75 (3H, s, OCH₃), 3.87 (1H, d, J = 12.2 Hz, H-CHHOH), 4.13 (1H, t, J = 6.9 Hz, H aliphatic fluorene), 4.21–4.41 (3H, m, CH₂-fluorene, Hα-tyrosyl), 4.95 (1H, d, J = 6.6 Hz, H-2'), 4.95 (1H, d, J = 6.6 Hz, H-4'), 5.82 (1H, br. s, NHFmoc), 6.21 (1H, br s, 3'-NH), 6.80 (2H, d, J = 8.4, Ph(OMe)), 7.09 (2H, d, J = 6.6 Hz, Ph(OMe)), 7.22–7.29 (2H, m, fluorene), 7.34 (2H, dd, J = 7.2, 4.8 Hz, fluorene), 7.49 (2H, dd, J = 7.2, 4.2 Hz, fluorene), 7.71 (2H, d, J = 7.5 Hz, fluorene), 8.23 (1H, s, H8), 8.26 (1H, s, H2); ¹³C-NMR (CDCl₃, 75 MHz) δ 9.5, 26.3, 35.3, 36.0, 37.8, 38.6, 47.0, 49.0, 55.1, 55.2, 56.5, 63.3, 67.1, 114.1, 120.0, 120.4, 124.9, 125.0 127.0, 127.7, 128.1, 130.3 137.3, 141.2, 143.6, 149.5, 151.8, 154.9, 156.1, 158.7, 172.1; HRMS (ESI⁺) calcd for (C₃₉H₄₂N₇O₅⁺) 688.3247 (MH⁺), found 688.3248.

(2S)-*N*-((1*R*,2*S*,4*S*,5*S*)-4-{6-[1-aza-2-(dibutylamino)vinyl]purin-9-yl}-1-(hydroxymethyl)bicyclo-[3.1.0]hex-2-yl)-2-[(fluoren-9-ylmethoxy)carbonylamino]-3-(4-methoxyphenyl)propanamide (23).

¹H-NMR (CDCl₃, 300 MHz) δ 0.52–0.60 (2H, m, H-6'a,b), 0.89–0.96 (6H, m, N(CH₂CH₂CH₂CH₃)₂), 1.30–1.41 (4H, m, N(CH₂CH₂CH₃)₂), 1.56–1.70 (6H, m, N(CH₂CH₂CH₂)₂, H-5', H-3'a), 1.99–2.10 (1H, m, H-3'b), 2.83–3.09 (2H, m, *p*-MeOPhCH₂), 3.21 (1H, d, *J* = 12.0 Hz, C*H*HOH), 3.37 (2H, t, *J* = 7.2 Hz, N(CH₂CH₂CH₂CH₃)₂), 3.66–3.73 (2H, m, N(CH₂CH₂CH₃)₂), 3.73 (3H, s, OCH₃), 3.87 (1H, d, *J* = 12.0 Hz, CHHOH), 4.07–4.15 (1H, m, aliphatic fluorene), 4.31–4.39 (3H, m, CH₂-fluorene, Hα-tyrosyl), 4.90–4.98 (2H, m, H-2', H-4'), 5.74 (1H, br. s, N*H*Fmoc), 6.32 (1H, br. s, 2'-N*H*), 6.79 (2H, d, *J* = 8.4 Hz, Ph(OMe), 7.07 (2H, br. s, Ph(OMe)), 7.22–7.27 (2H, m, fluorene), 7.34 (2H, dd, *J* = 12.9, 6.9 Hz, fluorene), 7.47–7.50 (2H, m, fluorene), 7.71 (2H, d, *J* = 6.9 Hz, fluorene), 8.36 (1H, s, H-8), 8.49 (1H, s, H-2), 9.02 (1H, s, N=CHNBu₂); ¹³C-NMR (CDCl₃, 75 MHz) δ 9.5, 13.6, 13.9, 19.7, 20.1, 26.2, 29.2, 30.9, 35.3, 36.1, 37.8, 45.2, 46.9, 49.0, 51.9, 55.2, 55.3, 56.4, 63.2, 67.0, 114.1, 119.9, 124.9, 125.0, 126.2, 127.0, 127.7, 128.2, 130.3, 140.6, 141.2, 143.6, 150.8, 152.2, 158.4, 158.6, 160.1, 162.3, 172.0; HRMS (ESI⁺) calcd for (C₄₆H₅₅N₈O₅⁺) 799.4295 (MH⁺), found 799.4297.

(2*S*)-*N*-{(1*S*,3*S*,4*S*,5*S*)-1-[6-(Dimethylamino)purin-9-yl]-4-(hydroxymethyl)bicyclo-[3.1.0]hex-3-yl}-2-(fluoren-9-ylmethoxy)carbonylamino]-3-(4-methoxyphenyl)propanamide (24).

¹H-NMR (CDCl₃, 300 MHz) δ 0.58 (2H, br. s, H-6'a), 1.09–1.15 (1H, m, H-6'b), 1.67 (1H, dd, J = 4.7, 9.5 Hz, H-5'), 1.91 (1H, br. s, H4'), 2.00 (1H, d, J = 13.8 Hz, H-2'a), 2.72 (1H, ddd, J = 13.8, 9.0, 1.8 Hz, H-2'b), 2.88 (1H, br s, *p*-MeOPhC*H*H), 3.06 (1H, br s, *p*-MeOPhC*HH*), 3.51 (6H, br s, NMe₂), 3.77 (3H, s, OC*H*₃), 3.87 (1H, dd, J = 11.6 Hz, J = 3.2 Hz, C*H*HOH), 4.01 (1H, d, J = 11.6 Hz, CHHOH), 4.21 (1H, t, J = 6.9 Hz, H aliphatic fluorene), 4.18–4.24 (1H, m, Hα-tyrosyl), 4.32–4.45 (3H, m, CH₂-fluorene, H-3'), 5.55 (2H, br s, 3'-N*H*, N*H*Fmoc), 6.86 (2H, d, J = 8.4 Hz, Ph(OMe)), 7.12 (2H, d, J = 4.5 Hz, Ph(OMe)), 7.31 (2H, td, J = 7.5, 0.9 Hz, fluorene), 7.40 (2H, t, J = 7.5 Hz, fluorene), 7.55 (2H, d, J = 7.5 Hz, fluorene), 7.63 (1H, s, H-8), 7.77 (2H, d, J = 7.5 Hz, fluorene), 8.26 (1H, s, H-2); ¹³C-NMR (CDCl₃, 75 MHz) δ 17.1, 27.4, 50.6, 38.1, 38.5, 40.9, 43.4, 47.0, 50.7, 53.6, 55.3, 56.6, 65.7, 67.2, 114.2, 120.1, 124.9, 125.0, 127.1, 127.8, 128.4, 130.3, 138.9, 141.3, 143.6, 150.1, 151.8, 155.0, 156.0, 158.8, 172.1; HRMS (ESI⁺) calcd for (C₃₉H₄₂N₇O₅⁺) 688.3247 (MH⁺), found : 688.3248.

(2*S*)-*N*-((1*S*,3*S*,4*S*,5*S*)-1-{6-[1-Aza-2-(dibutylamino)vinyl]purin-9-yl}-4-(hydroxymethyl)bicyclo-[3.1.0]hex-3-yl)-2-[(fluoren-9-ylmethoxy)carbonylamino]-3-(4-methoxyphenyl)propanamide (25).

¹H-NMR (CDCl₃, 300 MHz) δ 0.63 (1H, br. s, H-6'a), 0.88–0.96 (6H, m, N(CH₂CH₂CH₂CH₃)₂), 1.10 (1H, pseudo t, $J \approx 7.0$ Hz, H-6'b), 1.27–1.42 (4H, m, N(CH₂CH₂CH₂CH₃)₂), 1.55–1.69 (5H, m, N(CH₂CH₂CH₂CH₃)₂, H-5'), 1.95 (1H, s, H-4'), 2.03 (1H, d, J = 14.1 Hz, H-2'a), 2.71 (1H, dd, J = 12.6, 9.6 Hz, H-2'b), 2.87–2.94 (1H, m, *p*-MeOPhC*H*H), 3.03 (1H, br. s, *p*-MeOPhCH*H*), 3.37 (2H,

t, J = 7.1 Hz, N(CH₂CH₂CH₂CH₃)₂), 3.65–3.73 (2H, m, N(CH₂CH₂CH₂CH₃)₂), 3.75 (3H, s, OCH₃), 3.88 (1H, irregular t, J = 10.5, 7.5 Hz, CHHOH), 4.01 (1H, d, J = 11.4 Hz, CHHOH), 4.19 (1H, t, J = 6.9 Hz, aliphatic fluorene), 4.27–4.41 (4H, m, CH₂-fluorene, Hα-tyrosyl, H-3'), 5.88 (1H, br. s, NHFmoc), 6.42 (1H, d, J = 6.9 Hz, 3'-NH), 6.83 (2H, d, J = 8.7 Hz, Ph(OMe)), 7.10 (2H, d, J = 5.7 Hz, Ph(OMe)), 7.25–7.30 (2H, m, fluorene), 7.37 (2H, t, J = 7.4 Hz, fluorene), 7.53 (2H, d, J = 7.2 Hz, fluorene), 7.74 (2H, d, J = 8.1 Hz, fluorene), 7.75 (1H, s, H-8); 8.47 (1H, s, H-2), 8.95 (1H, s, N=CHNBu₂); ¹³C-NMR (CDCl₃, 75 MHz) δ 13.6, 13.8, 17.1, 19.7, 20.1, 27.3, 29.2, 30.9, 38.1, 40.8, 43.4, 45.2, 46.9, 50.5, 51.9, 53.6, 55.2, 56.5, 65.7, 67.2, 114.1, 120.0, 124.9, 125.0, 125.9, 127.0, 127.7, 128.4, 130.2, 141.2, 142.2, 143.5, 143.6, 151.2, 152.0, 158.2, 158.2, 158.7, 160.3, 170.3; HRMS (ESI⁺) calcd for (C₄₆H₅₅N₈O₅⁺) 799.4295 (MH+), found 799.4292.























والمرافع والمرافع فيستأثر فارتزل والمراقبة ومنتقدها فالمنافط فالمنافع فستعدد والمتراجين فالمراجع والمراجع المراف المتحالية فبالمتحالية والمنافعة المتلاحين المحدورة والمتحمون المتحد والمتحاطية والمتحالية فرابية والمتعالية والمتعا والمالية المالية أوالتا الكر الالمتلاقية ماذا أنشا فريته فالريار بالريادية GARTER PARTY TRAFT AND A THAT , det and a state of the data of the statement of the 50 150 100 ppm (t1) 30

 NH_2

Ν

15 ¹³C NMR

Ξ,,,

ΗÒ

TBDPSO



ppm (t1)

150

الأظلال الثلبي ومنتسان فالبارز المطالب الدير وسامر الرو فإصفين وبالاندونريل أفلا لالقلوب إر الأمالا الطريق والمتعاط يتورنه والمتعاط والمتعاول والمتعالية والمتعاول والمتعاولة والمتعاولة والمتعادي والمتعادي والمتعاد والمتعاد in the second L. Data d. Brown haters and the second i Malayar ar ta Shiri






















































Ximpurities & alkane impurity


































ppm (t1)

















































ppm (t1)

















ppm (t1)


























x impurities & alkane impurities







